Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LiveBioThx

Financiado

Live biotherapeutics to potentiate cancer immunotherapy

Immunotherapy, including immune checkpoint inhibitors (ICIs), has revolutionized the treatment of multiple cancers. Anti-tumor responses are often durable but overall only a subset of patients receiving ICIs has exhibited sustaine... ver más

31/08/2024

UCY

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITY OF CYPRUS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

UCY

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

EicoMet Targeting eicosanoid metabolism to overcome tumor immunosupp... 150K€ Cerrado

REACT Reprogramming of Tumor Stroma to Enhance Cancer Immunotherap... 150K€ Cerrado

EXPAND IT EXPANDing Immune Cells and their Tumor Antigens during check... 3M€ Cerrado

CANCER-DC Dissecting Regulatory Networks That Mediate Dendritic Cell S... 2M€ Cerrado

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2022-11-23
Fecha Fin: 2024-08-31

Líder del proyecto

UNIVERSITY OF CYPRUS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Immunotherapy, including immune checkpoint inhibitors (ICIs), has revolutionized the treatment of multiple cancers. Anti-tumor responses are often durable but overall only a subset of patients receiving ICIs has exhibited sustained tumor shrinkage, whereas a substantial fraction receiving these therapies develops immune-related adverse events. The absence of dramatic responses is attributed to several factors, including abnormalities in the tumor microenvironment (TME). Specifically, many tumors such as subsets of colorectal, breast and pancreatic cancer, become stiff as they grow. Tumor stiffening causes compression of intratumor blood vessels, impairing blood flow/perfusion and oxygen supply. Hypoperfusion reduces ICIs delivery to the tumor and hypoxia induces immunosuppression, compromising immunotherapy. To restore these abnormalities, a novel therapeutic strategy to normalize tumor stiffness prior to ICIs has been tested in preclinical studies and in the clinic. This strategy repurposes clinically approved drugs to target the factors contributing to tumor stiffening, leading to a new class of therapeutics, known as mechanotherapeutics. However, drug-repurposing poses certain limitations as adding a new drug to the treatment regimen of patients with cancer is not feasible in many cases. As an alternative to these approaches, we propose here to test the ability of engineered live biotherapeutics in the form of programmable bacteria that offer unique advantages for delivering enzymes to normalize the TME. Even a small fraction of bacterial dose reaching the tumor is sufficient to colonize it and allow therapeutic concentrations of tumor-remodeling enzymes to be maintained for a long period of time. We propose to evaluate the ability of a novel live biotherapeutic product to improve perfusion and potentiate ICIs in preclinical tumor models of colorectal and breast tumors. This bacterial product has great potential for commercialization, and a plan is proposed.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores